GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Iterum Therapeutics PLC (NAS:ITRM) » Definitions » PB Ratio

ITRM (Iterum Therapeutics) PB Ratio : (As of Mar. 28, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Iterum Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2025-03-28), Iterum Therapeutics's share price is $1.29. Iterum Therapeutics's Book Value per Share for the quarter that ended in Sep. 2024 was $-0.13. Hence, Iterum Therapeutics's PB Ratio of today is .

The historical rank and industry rank for Iterum Therapeutics's PB Ratio or its related term are showing as below:

During the past 9 years, Iterum Therapeutics's highest PB Ratio was 4.08. The lowest was 0.79. And the median was 1.30.

ITRM's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.395
* Ranked among companies with meaningful PB Ratio only.

During the past 12 months, Iterum Therapeutics's average Book Value Per Share Growth Rate was -308.60% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 68.60% per year.

During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Iterum Therapeutics was 68.60% per year. The lowest was -62.00% per year. And the median was 3.30% per year.

Back to Basics: PB Ratio


Iterum Therapeutics PB Ratio Historical Data

The historical data trend for Iterum Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Iterum Therapeutics PB Ratio Chart

Iterum Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
PB Ratio
Get a 7-Day Free Trial Premium Member Only - 1.43 0.38 - -

Iterum Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Iterum Therapeutics's PB Ratio

For the Biotechnology subindustry, Iterum Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Iterum Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Iterum Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Iterum Therapeutics's PB Ratio falls into.


;
;

Iterum Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Iterum Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Sep. 2024)
=1.29/-0.129
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Iterum Therapeutics  (NAS:ITRM) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Iterum Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Iterum Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Iterum Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
3 Dublin Landings, North Wall Quay, Dublin 1, Dublin, IRL, D01 C4E0
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
Executives
Michael W. Dunne officer: Chief Scientific Officer DURATA THERAPEUTICS, INC., 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR, MORRISTOWN NJ 07960
Fishman Corey N. director, officer: President & CEO DURATA THERAPEUTICS, INC., 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR, MORRISTOWN NJ 07960
Sailaja Puttagunta officer: Chief Medical Officer C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Brenton Karl Ahrens director 2765 SAND HILL ROAD, MENLO PARK CA 94025
Judith M. Matthews officer: Chief Financial Officer 200 WEST MONROE ST., SUITE 1575, CHICAGO IL 60606
Beth Hecht director C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 360, GRAND PRAIRIE TX 75050
Alexander J Denner 10 percent owner C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarissa Capital Hawkeye Fund Lp 10 percent owner 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarissa Capital Catapult Fund Llc 10 percent owner 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarissa Capital Master Fund Ii Lp 10 percent owner C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarissa Capital Offshore Master Fund Lp 10 percent owner C/O SARISSA CAPITAL MANAGEMENT, 660 STEAMBOAT ROAD 3RD FLOOR, GREENWICH CT 06830
Sarissa Capital Management Lp 10 percent owner 660 STEAMBOAT ROAD, GREENWICH CT 06830
Peter Kolchinsky 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p. 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116